Money Report

European markets were mixed on Friday as investors look ahead to highly anticipated fiscal stimulus from China.

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly.

Russia’s war-orientated economy and military spending plans risk deepening major imbalances within the government’s finances, analysts say.

Tesla’s long-awaited robotaxi event started almost an hour late on Thursday and included more big promises from Elon Musk.

JPMorgan will be watched closely for clues on how banks are faring at the start of the Federal Reserve’s easing cycle.

Investors are on tenterhooks as Beijing prepares to deliver fresh policies to boost its economy.

It’s important to see whether individual data points cohere into a larger pattern, or if they’re just “janky,” as Atlanta Fed President Raphael Bostic put it.

The BOK cut its benchmark interest rate from 3.5% to 3.25% after a “clear trend of stabilization” with inflation.

Microsoft is keen on boosting its mobile gaming position. A judge’s decision this week opened the way to do so on Android devices.

Mainland China’s CSI 300 blue chip index extended weekly declines, as the stimulus-fueled rally continues to lose steam.

The S&P 500 and the Dow retreated from their records on Thursday, as an inflation report weighed on stocks. Here’s what CNBC is watching going into Friday.

He is the head honcho of one of Southeast Asia’s biggest tech companies, Grab — but he’ll be the first to say that the journey has not been easy.

CNBC’s Jim Cramer reviewed stocks that led the market cap-weighted index to new heights over the past two years.